福利斯塔丁可以降低血压,改善血管结构和功能,治疗基本和二次高血压
Ann Kuganathan1, Marcos Leal1, Neel Mehta1
1Division of Nephrology, Department of Medicine, McMaster University, Hamilton, ON, Canada.
概括
富利斯塔丁是一种活性蛋白A抗剂,在高血压模型中有效降低血压并改善血管健康. 这表明其作为一种新型抗高血压疗法的潜力,通过减少氧化应激和纤维化.
科学领域:
- 心血管研究研究心血管研究
- 腎臟病學 (nephrology) 是一種醫學.
- 内分泌学 在内分泌学.
背景情况:
- 高血压涉及阻力动脉改造,由氧化应激和纤维化驱动.
- 之前的研究表明,在慢性病模型中,利沙丁抑制脏氧化应激和纤维化.
研究的目的:
- 在基本和二次高血压模型中研究利斯塔丁对血压,血管结构和功能的影响.
- 探索利沙丁作为抗高血压剂的治疗潜力.
主要方法:
- 在5/6个腎切除小鼠 (二次高血壓) 和自發高血壓老鼠 (基本高血壓) 中,folistatin治療.
- 血液压力测量通过尾部袖口和射电测量.
- 介质动脉的血管结构和功能分析.
- 在孤立的血管中评估氧化应激和activin A的影响.
主要成果:
- 在这两种高血压模型中,folistatin显著降低了血压.
- 改善了血管结构,包括减少了中间厚度和原含量.
- 减少最大收缩和增强内皮依赖放松.
- 减弱的血管氧化应激,与activinA显示增加氧化应激和损害放松.
结论:
- 在基本和二次高血压模型中,folistatin通过改善血管结构和功能来显示抗高血压作用.
- 该机制涉及对抗激素A和抑制氧化应激.
- 福利斯塔丁表明作为高血压治疗的新型治疗剂具有前途.
相关概念视频
Hypertension and Regulation of Blood Pressure
1.9K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
1.9K
Factors affecting Blood pressure
3.0K
Several physiological and lifestyle factors influence blood pressure (BP). Understanding these factors is crucial as they are significant in patient education and blood pressure management.
Physiological Factors:
Physiological Factors:
3.0K
Hormonal Regulation of Blood Pressure
2.5K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
2.5K
Antihypertensive Drugs: Angiotensin II Receptor Blockers
600
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
600
Antihypertensive Drugs: Direct Renin Inhibitors
508
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
508
Antihypertensive Drugs: Vasodilators
491
Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
491


